Prostate Cancer - Results from #25600

Janssen submits additional marketing applications for ZYTIGA® in the U.S. and European Union June 20, 2012

Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers - Abstract June 19, 2012

The role of distal third radius dual energy X-ray absorptiometry (DXA) and central DXA in evaluating for osteopenia and osteoporosis in men receiving androgen deprivation therapy for prostate cancer - Abstract June 19, 2012

Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer - Abstract June 19, 2012

Accuracy of real-time couch tracking during 3-dimensional conformal radiation therapy, intensity modulated radiation therapy, and volumetric modulated arc therapy for prostate cancer - Abstract June 19, 2012

Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial - Abstract June 19, 2012

Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer - Abstract June 19, 2012

The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of ≥3.0 ng/mL is an independent risk factor for prostate cancer: Results from the Gothenburg Randomized Screening Trial - Abstract June 19, 2012

Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy - Abstract June 19, 2012

Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer - Abstract June 19, 2012

Prostate cancer and occupational whole-body vibration exposure - Abstract June 19, 2012

BJUI Mini Reviews - Quality-of-care framework in urological cancers: Where do we stand? June 19, 2012

The impact of multiple biopsies on outcomes of nerve-sparing robotic-assisted radical prostatectomy - Abstract June 18, 2012

Clinical development of novel therapeutics for castration-resistant prostate cancer: Historic challenges and recent successes - Abstract June 18, 2012

Multiparametric 3T endorectal MRI after external beam radiation therapy for prostate cancer - Abstract June 18, 2012

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer - Abstract June 18, 2012

Interpreting results from oncology clinical trials: A comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients - Abstract June 18, 2012

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? - Abstract June 18, 2012

Historical prostate cancer screening and treatment outcomes from a single institution - Abstract June 18, 2012

Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer - Abstract June 18, 2012

Page 1281 of 1437